5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Increased O
Mortality O
, O
Myocardial O
Infarction O
, O
Stroke O
, O
and O
Thromboembolism O
: O
Using O
Aranesp O
to O
target O
a O
hemoglobin O
level O
of O
greater O
than O
11 O
g/dL O
increases O
the O
risk O
of O
serious O
adverse O
cardiovascular O
reactions O
and O
has O
not O
been O
shown O
to O
provide O
additional O
benefit O
( O
5.1 O
and O
14.1 O
) O
. O

Use O
caution O
in O
patients O
with O
coexistent O
cardiovascular O
disease O
and O
stroke O
( O
5.1 O
) O
. O

* O
Increased O
Mortality O
and/or O
Increased O
Risk O
of O
Tumor O
Progression O
or O
Recurrence O
in O
Patients O
with O
Cancer O
( O
5.2 O
) O
. O

* O
Hypertension O
: O
Control O
hypertension O
prior O
to O
initiating O
and O
during O
treatment O
with O
Aranesp O
( O
5.3 O
) O
. O

* O
Seizures O
: O
Aranesp O
increases O
the O
risk O
for O
seizures O
in O
patients O
with O
CKD O
( O
5.4 O
) O
.Increase O
monitoring O
of O
these O
patients O
for O
changes O
in O
seizure O
frequency O
or O
premonitory O
symptoms O
( O
5.4 O
) O
. O

* O
PRCA O
: O
If O
severe O
anemia O
and O
low O
reticulocyte O
count O
develop O
during O
Aranesp O
treatment O
, O
withhold O
Aranesp O
and O
evaluate O
for O
PRCA O
( O
5.6 O
) O
. O

* O
Serious O
Allergic O
Reactions O
: O
Discontinue O
Aranesp O
and O
manage O
reactions O
( O
5.7 O
) O
. O

* O
Severe O
Cutaneous O
Reactions O
: O
Discontinue O
Aranesp O
( O
5.8 O
) O
. O

5.1 O
Increased O
Mortality O
, O
Myocardial O
Infarction O
, O
Stroke O
, O
and O
Thromboembolism O
* O
In O
controlled O
clinical O
trials O
of O
patients O
with O
CKD B-Not_AE_Candidate
comparing O
higher O
hemoglobin O
targets O
( O
13 O
- O
14 O
g/dL O
) O
to O
lower O
targets O
( O
9 O
- O
11.3 O
g/dL O
) O
, O
Aranesp O
and O
other O
ESAs O
increased O
the O
risk O
of O
death B-NonOSE_AE
, O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
of I-OSE_Labeled_AE
hemodialysis I-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
access I-OSE_Labeled_AE
, O
and O
other O
thromboembolic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
higher O
target O
groups O
. O

* O
Using O
Aranesp O
to O
target O
a O
hemoglobin B-NonOSE_AE
level I-NonOSE_AE
of I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
1 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
increases O
the O
risk O
of O
serious O
adverse B-NonOSE_AE
cardiovascular I-NonOSE_AE
reactions I-NonOSE_AE
and O
has O
not O
been O
shown O
to O
provide O
additional O
benefit O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Use O
caution O
in O
patients O
with O
coexistent O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
stroke B-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

Patients O
with O
CKD B-Not_AE_Candidate
and O
an O
insufficient O
hemoglobin O
response O
to O
ESA O
therapy O
may O
be O
at O
even O
greater O
risk O
for O
cardiovascular B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
mortality B-NonOSE_AE
than O
other O
patients O
. O

A O
rate O
of O
hemoglobin B-NonOSE_AE
rise I-NonOSE_AE
of I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
over I-NonOSE_AE
2 I-NonOSE_AE
weeks I-NonOSE_AE
may O
contribute O
to O
these O
risks O
. O

* O
In O
controlled O
clinical O
trials O
of O
patients O
with O
cancer B-Not_AE_Candidate
, O
Aranesp O
and O
other O
ESAs O
increased O
the O
risks O
for O
death B-NonOSE_AE
and O
serious O
adverse B-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

These O
adverse O
reactions O
included O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
and O
stroke B-OSE_Labeled_AE
. O

* O
In O
controlled O
clinical O
trials O
, O
ESAs O
increased O
the O
risk O
of O
death B-NonOSE_AE
in O
patients O
undergoing O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
and O
the O
risk O
of O
deep B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
( O
DVT O
) O
in O
patients O
undergoing O
orthopedic O
procedures O
. O

The O
design O
and O
overall O
results O
of O
the O
3 O
large O
trials O
comparing O
higher B-NonOSE_AE
and I-NonOSE_AE
lower I-NonOSE_AE
hemoglobin I-NonOSE_AE
targets I-NonOSE_AE
are O
shown O
in O
Table O
3 O
. O

Table O
3 O
: O
Randomized O
Controlled O
Trials O
Showing O
Adverse O
Cardiovascular O
Outcomes O
in O
Patients O
with O
CKD O
Normal O
Hematocrit O
Study O
( O
NHS O
) O
( O
N O
= O
12 O
65 O
) O
CHOIR O
( O
N O
= O
1432 O
) O
TREAT O
( O
N O
= O
4038 O
) O
Time O
Period O
of O
Trial O
1993 O
to O
1996 O
2003 O
to O
2006 O
2004 O
to O
2009 O
Population O
Adult O
patients O
with O
CKD O
on O
hemodialysis O
with O
coexisting O
CHF O
or O
CAD O
, O
hematocrit O
30 O
+/- O
3 O
% O
on O
epoetin O
alfa O
Adult O
patients O
with O
CKD O
not O
on O
dialysis O
with O
hemoglobin O
< O
11 O
g/dL O
not O
previously O
administered O
epoetin O
alfa O
Adult O
patients O
with O
CKD O
not O
on O
dialysis O
with O
type O
II O
diabetes O
, O
hemoglobin O
< O
= O
11 O
g/dL O
Hemoglobin O
Target O
; O
Higher O
vs O
. O
Lower O
( O
g/dL O
) O
14.0 O
vs O
. O
10.0 O
13.5 O
vs O
. O
11.3 O
13.0 O
vs O
. O
> O
= O
9.0 O
Median O
( O
Q1 O
, O
Q3 O
) O
Achieved O
Hemoglobin O
level O
( O
g/dL O
) O
12.6 O
( O
11.6 O
, O
13.3 O
) O
vs O
. O
10.3 O
( O
10.0 O
, O
10.7 O
) O
13.0 O
( O
12.2 O
, O
13.4 O
) O
vs O
. O
11.4 O
( O
11.1 O
, O
11.6 O
) O
12.5 O
( O
12.0 O
, O
12.8 O
) O
vs O
. O
10.6 O
( O
9.9 O
, O
11.3 O
) O
Primary O
Endpoint O
All-cause O
mortality O
or O
non-fatal O
MI O
All-cause O
mortality O
, O
MI O
, O
hospitalization O
for O
CHF O
, O
or O
stroke O
All-cause O
mortality O
, O
MI O
, O
myocardial O
ischemia O
, O
heart O
failure O
, O
and O
stroke O
Hazard O
Ratio O
or O
Relative O
Risk O
( O
95 O
% O
CI O
) O
1.28 O
( O
1.06 O
- O
1.56 O
) O
1.34 O
( O
1.03 O
- O
1.74 O
) O
1.05 O
( O
0.94 O
- O
1.17 O
) O
Adverse O
Outcome O
for O
Higher O
Target O
Group O
All-cause O
mortality O
All-cause O
mortality O
Stroke O
Hazard O
Ratio O
or O
Relative O
Risk O
( O
95 O
% O
CI O
) O
1.27 O
( O
1.04 O
- O
1.54 O
) O
1.48 O
( O
0.97 O
- O
2.27 O
) O
1.92 O
( O
1.38 O
- O
2.68 O
) O
Patients O
with O
Chronic O
Kidney O
Disease O
Normal O
Hematocrit O
Study O
( O
NHS O
) O
: O
A O
prospective O
, O
randomized O
, O
open-label O
study O
of O
1265 O
patients O
with O
chronic B-Not_AE_Candidate
kidney I-Not_AE_Candidate
disease I-Not_AE_Candidate
on O
dialysis O
with O
documented O
evidence O
of O
congestive B-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
or O
ischemic B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
was O
designed O
to O
test O
the O
hypothesis O
that O
a O
higher O
target O
hematocrit O
( O
Hct O
) O
would O
result O
in O
improved O
outcomes O
compared O
with O
a O
lower O
target O
Hct O
. O

In O
this O
study O
, O
patients O
were O
randomized O
to O
epoetin O
alfa O
treatment O
targeted O
to O
a O
maintenance O
hemoglobin O
of O
either O
14 O
+/- O
1 O
g/dL O
or O
10 O
+/- O
1 O
g/dL O
. O

The O
trial O
was O
terminated O
early O
with O
adverse O
safety O
findings O
of O
higher O
mortality B-NonOSE_AE
in O
the O
high O
hematocrit O
target O
group O
. O

Higher O
mortality B-NonOSE_AE
( O
35 O
% O
vs O
. O
29 O
% O
) O
was O
observed O
for O
the O
patients O
randomized O
to O
a O
target O
hemoglobin O
of O
14 O
g/dL O
than O
for O
the O
patients O
randomized O
to O
a O
target O
hemoglobin O
of O
10 O
g/dL O
. O

For O
all-cause O
mortality B-NonOSE_AE
, O
the O
HR O
= O
1.27 O
; O
95 O
% O
CI O
( O
1.04 O
, O
1.54 O
) O
; O
p=0.018 O
. O

The O
incidence O
of O
nonfatal B-NonOSE_AE
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
vascular B-NonOSE_AE
access I-NonOSE_AE
thrombosis I-NonOSE_AE
, O
and O
other O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
was O
also O
higher O
in O
the O
group O
randomized O
to O
a O
target O
hemoglobin O
of O
14 O
g/dL O
. O

CHOIR O
: O
A O
randomized O
, O
prospective O
trial O
, O
1432 O
patients O
with O
anemia B-Not_AE_Candidate
due I-Not_AE_Candidate
to I-Not_AE_Candidate
CKD I-Not_AE_Candidate
who O
were O
not O
undergoing O
dialysis O
and O
who O
had O
not O
previously O
received O
epoetin O
alfa O
therapy O
were O
randomized O
to O
epoetin O
alfa O
treatment O
targeting O
a O
maintenance O
hemoglobin O
concentration O
of O
either O
13.5 O
g/dL O
or O
11.3 O
g/dL O
. O

The O
trial O
was O
terminated O
early O
with O
adverse O
safety O
findings O
. O

A O
major B-NonOSE_AE
cardiovascular I-NonOSE_AE
event I-NonOSE_AE
( O
death B-NonOSE_AE
, O
myocardial B-NonOSE_AE
infarction I-NonOSE_AE
, O
stroke B-NonOSE_AE
, O
or O
hospitalization O
for O
congestive B-NonOSE_AE
heart I-NonOSE_AE
failure I-NonOSE_AE
) O
occurred O
in O
125 O
of O
the O
715 O
patients O
( O
18 O
% O
) O
in O
the O
higher O
hemoglobin O
group O
compared O
to O
97 O
of O
the O
717 O
patients O
( O
14 O
% O
) O
in O
the O
lower O
hemoglobin O
group O
[ O
hazard O
ratio O
( O
HR O
) O
1.34 O
, O
95 O
% O
CI O
: O
1.03 O
, O
1.74 O
; O
p O
= O
0.03 O
] O
. O

TREAT O
: O
A O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
prospective O
trial O
of O
4038 O
patients O
with O
CKD B-Not_AE_Candidate
not O
on O
dialysis O
( O
eGFR O
of O
20 O
- O
60 O
mL/min O
) O
, O
anemia B-Not_AE_Candidate
( O
hemoglobin B-NonOSE_AE
levels I-NonOSE_AE
< I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
1 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
, O
and O
type B-Not_AE_Candidate
2 I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
patients O
were O
randomized O
to O
receive O
either O
Aranesp O
treatment O
or O
a O
matching O
placebo O
. O

Placebo O
group O
patients O
also O
received O
Aranesp O
when O
their O
hemoglobin O
levels O
were O
below O
9 O
g/dL O
. O

The O
trial O
objectives O
were O
to O
demonstrate O
the O
benefit O
of O
Aranesp O
treatment O
of O
the O
anemia B-Not_AE_Candidate
to O
a O
target O
hemoglobin O
level O
of O
13 O
g/dL O
, O
when O
compared O
to O
a O
`` O
placebo O
'' O
group O
, O
by O
reducing O
the O
occurrence O
of O
either O
of O
two O
primary O
endpoints O
: O
( O
1 O
) O
a O
composite O
cardiovascular O
endpoint O
of O
all-cause O
mortality B-NonOSE_AE
or O
a O
specified O
cardiovascular B-NonOSE_AE
event I-NonOSE_AE
( O
myocardial B-NonOSE_AE
ischemia I-NonOSE_AE
, O
CHF B-NonOSE_AE
, O
MI B-NonOSE_AE
, O
and O
CVA B-NonOSE_AE
) O
or O
( O
2 O
) O
a O
composite O
renal O
endpoint O
of O
all-cause O
mortality B-NonOSE_AE
or O
progression O
to O
end B-NonOSE_AE
stage I-NonOSE_AE
renal I-NonOSE_AE
disease I-NonOSE_AE
. O

The O
overall O
risks O
for O
each O
of O
the O
two O
primary O
endpoints O
( O
the O
cardiovascular O
composite O
and O
the O
renal O
composite O
) O
were O
not O
reduced O
with O
Aranesp O
treatment O
( O
see O
Table3 O
) O
, O
but O
the O
risk O
of O
stroke B-NonOSE_AE
was O
increased O
nearly O
two-fold O
in O
the O
Aranesp-treated O
group O
versus O
the O
placebo O
group O
: O
annualized O
stroke B-NonOSE_AE
rate O
2.1 O
% O
vs O
. O
1.1 O
% O
, O
respectively O
, O
HR O
1.92 O
; O
95 O
% O
CI O
: O
1.38 O
, O
2.68 O
; O
p O
< O
0.001 O
. O

The O
relative O
risk O
of O
stroke B-NonOSE_AE
was O
particularly O
high O
in O
patients O
with O
a O
prior O
stroke B-Not_AE_Candidate
: O
annualized O
stroke B-NonOSE_AE
rate O
5.2 O
% O
in O
the O
Aranesp O
treated O
group O
and O
1.9 O
% O
in O
the O
placebo O
group O
, O
HR O
3.07 O
; O
95 O
% O
CI O
: O
1.44 O
, O
6.54 O
. O

Also O
, O
among O
Aranesp-treated O
subjects O
with O
a O
past O
history O
of O
cancer B-Not_AE_Candidate
, O
there O
were O
more O
deaths B-NonOSE_AE
due O
to O
all O
causes O
and O
more O
deaths B-NonOSE_AE
adjudicated O
as O
due O
to O
cancer B-NonOSE_AE
, O
in O
comparison O
with O
the O
control O
group O
. O

Patients O
with O
Cancer O
An O
increased O
incidence O
of O
thromboembolic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
some O
serious O
and O
life-threatening O
, O
occurred O
in O
patients O
with O
cancer B-Not_AE_Candidate
treated O
with O
ESAs O
. O

In O
a O
randomized O
, O
placebo-controlled O
study O
( O
Study O
2 O
in O
Table O
4 O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
) O
of O
939 O
women O
with O
metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
chemotherapy O
, O
patients O
received O
either O
weekly O
epoetin O
alfa O
or O
placebo O
for O
up O
to O
a O
year O
. O

This O
study O
was O
designed O
to O
show O
that O
survival O
was O
superior O
when O
epoetin O
alfa O
was O
administered O
to O
prevent O
anemia B-NonOSE_AE
( O
maintain O
hemoglobin O
levels O
between O
12 O
and O
14 O
g/dL O
or O
hematocrit O
between O
36 O
% O
and O
42 O
% O
) O
. O

This O
study O
was O
terminated O
prematurely O
when O
interim O
results O
demonstrated O
a O
higher O
mortality B-NonOSE_AE
at O
4 O
months O
( O
8.7 O
% O
vs O
. O
3.4 O
% O
) O
and O
a O
higher O
rate O
of O
fatal B-NonOSE_AE
thrombotic B-NonOSE_AE
reactions I-NonOSE_AE
( O
1.1 O
% O
vs O
. O
0.2 O
% O
) O
in O
the O
first O
4 O
months O
of O
the O
study O
among O
patients O
treated O
with O
epoetin O
alfa O
. O

Based O
on O
Kaplan-Meier O
estimates O
, O
at O
the O
time O
of O
study O
termination O
, O
the O
12-month O
survival O
was O
lower O
in O
the O
epoetin O
alfa O
group O
than O
in O
the O
placebo O
group O
( O
70 O
% O
vs O
. O
76 O
% O
; O
HR O
1.37 O
, O
95 O
% O
CI O
: O
1.07 O
, O
1.75 O
; O
p O
= O
0.012 O
) O
. O

Patients O
Having O
Surgery O
Aranesp O
is O
not O
approved O
for O
reduction O
of O
RBC O
transfusions O
in O
patients O
scheduled O
for O
surgical O
procedures O
. O

An O
increased O
incidence O
of O
DVT B-OSE_Labeled_AE
in O
patients O
receiving O
epoetin O
alfa O
undergoing O
surgical O
orthopedic O
procedures O
was O
demonstrated O
. O

In O
a O
randomized O
, O
controlled O
study O
, O
680 O
adult O
patients O
, O
not O
receiving O
prophylactic O
anticoagulation O
and O
undergoing O
spinal O
surgery O
, O
received O
epoetin O
alfa O
and O
standard O
of O
care O
( O
SOC O
) O
treatment O
( O
n O
= O
340 O
) O
or O
SOC O
treatment O
alone O
( O
n O
= O
340 O
) O
. O

A O
higher O
incidence O
of O
DVTs B-OSE_Labeled_AE
, O
determined O
by O
either O
color O
flow O
duplex O
imaging O
or O
by O
clinical O
symptoms O
, O
was O
observed O
in O
the O
epoetin O
alfa O
group O
( O
16 O
[ O
4.7 O
% O
] O
patients O
) O
compared O
with O
the O
SOC O
group O
( O
7 O
[ O
2.1 O
% O
] O
patients O
) O
. O

In O
addition O
to O
the O
23 O
patients O
with O
DVTs B-OSE_Labeled_AE
included O
in O
the O
primary O
analysis O
, O
19 O
[ O
2.8 O
% O
] O
patients O
experienced O
1 O
other O
thrombovascular B-OSE_Labeled_AE
event I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TVE I-OSE_Labeled_AE
) O
each O
( O
12 O
[ O
3.5 O
% O
] O
in O
the O
epoetin O
alfa O
group O
and O
7 O
[ O
2.1 O
% O
] O
in O
the O
SOC O
group O
) O
. O

Increased O
mortality B-NonOSE_AE
was O
observed O
in O
a O
randomized O
, O
placebo-controlled O
study O
of O
epoetin O
alfa O
in O
adult O
patients O
who O
were O
undergoing O
CABG O
surgery O
( O
7 O
deaths B-NonOSE_AE
in O
126 O
patients O
randomized O
to O
epoetin O
alfa O
versus O
no O
deaths B-NonOSE_AE
among O
56 O
patients O
receiving O
placebo O
) O
. O

Four O
of O
these O
deaths B-NonOSE_AE
occurred O
during O
the O
period O
of O
study O
drug O
administration O
and O
all O
4 O
deaths B-NonOSE_AE
were O
associated O
with O
thrombotic B-NonOSE_AE
events I-NonOSE_AE
. O

5.2 O
Increased O
Mortality O
and/or O
Increased O
Risk O
of O
Tumor B-OSE_Labeled_AE
Progression I-OSE_Labeled_AE
or O
Recurrence O
in O
Patients O
with O
Cancer O
ESAs O
resulted O
in O
decreased O
locoregional O
control/progression-free O
survival O
( O
PFS O
) O
and/or O
overall O
survival O
( O
OS O
) O
( O
see O
Table O
4 O
) O
. O

Adverse O
effects O
on O
PFS O
and/or O
OS O
were O
observed O
in O
studies O
of O
patients O
receiving O
chemotherapy O
for O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
Studies O
1 O
, O
2 O
, O
and O
4 O
) O
, O
lymphoid B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
Study O
3 O
) O
, O
and O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
Study O
5 O
) O
; O
in O
patients O
with O
advanced O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
radiation O
therapy O
( O
Studies O
6 O
and O
7 O
) O
, O
and O
in O
patients O
with O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
small I-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
or O
various O
malignancies O
who O
were O
not O
receiving O
chemotherapy O
or O
radiotherapy O
( O
Studies O
8 O
and O
9 O
) O
. O

Table O
4 O
. O

Randomized O
, O
Controlled O
Studies O
with O
Decreased O
Survival O
and/or O
Decreased O
Locoregional O
Control O
Study/Tumor/ O
( O
n O
) O
Hemoglobin O
Target O
Hemoglobin O
( O
Median O
; O
Q1 O
, O
Q3* O
) O
Primary O
Efficacy O
Outcome O
Adverse O
Outcome O
for O
ESA O
- O
containing O
Arm O
Chemotherapy O
Study O
1 O
Metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
2098 O
) O
< O
=12 O
g/dL O
11.6 O
g/dL O
; O
10.7 O
, O
12.1 O
g/dL O
Progression-freesurvival O
( O
PFS O
) O
Decreased O
progression-free O
and O
overall O
survival O
Study O
2 O
Metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
939 O
) O
12-14 O
g/dL O
12.9 O
g/dL O
; O
12.2 O
, O
13.3 O
g/dL O
12-month O
overall O
survival O
Decreased O
12-month O
survival O
Study O
3 O
Lymphoid B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
n O
= O
344 O
) O
13-15 O
g/dL O
( O
M O
) O
13-14 O
g/dL O
( O
F O
) O
11 O
g/dL O
; O
9.8 O
, O
12.1 O
g/dL O
Proportion O
of O
patients O
achieving O
a O
hemoglobin O
response O
Decreased O
overall O
survival O
Study O
4 O
Early O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
733 O
) O
12.5-13 O
g/dL O
13.1 O
g/dL O
; O
12.5 O
, O
13.7 O
g/dL O
Relapse-free O
and O
overall O
survival O
Decreased O
3-year O
relapse-free O
and O
overall O
survival O
Study O
5 O
Cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
114 O
) O
12-14 O
g/dL O
12.7 O
g/dL O
; O
12.1 O
, O
13.3 O
g/dL O
Progression-free O
and O
overall O
survival O
and O
locoregional O
control O
Decreased O
3-year O
progression-free O
and O
overall O
survival O
and O
locoregional O
control O
Radiotherapy O
Alone O
Study O
6 O
Head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
351 O
) O
> O
= O
15 O
g/dL O
( O
M O
) O
> O
= O
14 O
g/dL O
( O
F O
) O
Not O
available O
Locoregional O
progression-free O
survival O
Decreased O
5-year O
locoregional O
progression-free O
and O
overall O
survival O
Study O
7 O
Head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
522 O
) O
14-15.5 O
g/dL O
Not O
available O
Locoregional O
disease O
control O
Decreased O
locoregional O
disease O
control O
No O
Chemotherapy O
or O
Radiotherapy O
Study O
8 O
Non B-Not_AE_Candidate
- I-Not_AE_Candidate
small I-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
( O
n O
= O
70 O
) O
12-14 O
g/dL O
Not O
available O
Quality O
of O
life O
Decreased O
overall O
survival O
Study O
9 O
Non B-Not_AE_Candidate
- I-Not_AE_Candidate
myeloid I-Not_AE_Candidate
malignancy I-Not_AE_Candidate
( O
n O
= O
989 O
) O
12-13 O
g/dL O
10.6 O
g/dL O
; O
9.4 O
, O
11.8 O
g/dL O
RBC O
transfusions O
Decreased O
overall O
survival O
*Q1 O
= O
25th O
percentile O
Q3 O
= O
75th O
percentile O
This O
study O
did O
not O
include O
a O
defined O
hemoglobin O
target O
. O

Doses O
were O
titrated O
to O
achieve O
and O
maintain O
the O
lowest O
hemoglobin O
level O
sufficient O
to O
avoid O
transfusion O
and O
not O
to O
exceed O
12 O
g/dL O
. O

Decreased O
Overall O
Survival O
Study O
2 O
was O
described O
in O
the O
previous O
section O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Mortality B-NonOSE_AE
at O
4 O
months O
( O
8.7 O
% O
vs O
. O
3.4 O
% O
) O
was O
significantly O
higher O
in O
the O
epoetin O
alfa O
arm O
. O

The O
most O
common O
investigator-attributed O
cause O
of O
death B-NonOSE_AE
within O
the O
first O
4 O
months O
was O
disease O
progression O
; O
28 O
of O
41 O
deaths B-NonOSE_AE
in O
the O
epoetin O
alfa O
arm O
and O
13 O
of O
16 O
deaths B-NonOSE_AE
in O
the O
placebo O
arm O
were O
attributed O
to O
disease O
progression O
. O

Investigator-assessed O
time O
to O
tumor B-NonOSE_AE
progression I-NonOSE_AE
was O
not O
different O
between O
the O
2 O
groups O
. O

Survival O
at O
12 O
months O
was O
significantly O
lower O
in O
the O
epoetin O
alfa O
arm O
( O
70 O
% O
vs O
. O
76 O
% O
; O
HR O
1.37 O
, O
95 O
% O
CI O
: O
1.07 O
, O
1.75 O
; O
p O
= O
0.012 O
) O
. O

Study O
3 O
was O
a O
randomized O
, O
double-blind O
study O
( O
darbepoetin O
alfa O
vs O
. O
placebo O
) O
conducted O
in O
344 O
anemic B-Not_AE_Candidate
patients O
with O
lymphoid B-Not_AE_Candidate
malignancy I-Not_AE_Candidate
receiving O
chemotherapy O
. O

With O
a O
median O
follow-up O
of O
29 O
months O
, O
overall O
mortality B-NonOSE_AE
rates O
were O
significantly O
higher O
among O
patients O
randomized O
to O
darbepoetin O
alfa O
as O
compared O
to O
placebo O
( O
HR O
1.36 O
, O
95 O
% O
CI O
: O
1.02 O
, O
1.82 O
) O
. O

Study O
8 O
was O
a O
multicenter O
, O
randomized O
, O
double-blind O
study O
( O
epoetin O
alfa O
vs O
. O
placebo O
) O
in O
which O
patients O
with O
advanced B-Not_AE_Candidate
non I-Not_AE_Candidate
- I-Not_AE_Candidate
small I-Not_AE_Candidate
cell I-Not_AE_Candidate
lung I-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
only O
palliative O
radiotherapy O
or O
no O
active O
therapy O
were O
treated O
with O
epoetin O
alfa O
to O
achieve O
and O
maintain O
hemoglobin O
levels O
between O
12 O
and O
14 O
g/dL O
. O

Following O
an O
interim O
analysis O
of O
70 O
patients O
( O
planned O
accrual O
300 O
patients O
) O
, O
a O
significant O
difference O
in O
survival O
in O
favor O
of O
the O
patients O
in O
the O
placebo O
arm O
of O
the O
study O
was O
observed O
( O
median O
survival O
63 O
vs O
. O
129 O
days O
; O
HR O
1.84 O
; O
p O
= O
0.04 O
) O
. O

Study O
9 O
was O
a O
randomized O
, O
double-blind O
study O
( O
darbepoetin O
alfa O
vs O
. O
placebo O
) O
in O
989 O
anemic B-Not_AE_Candidate
patients O
with O
active B-Not_AE_Candidate
malignant I-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
neither O
receiving O
nor O
planning O
to O
receive O
chemotherapy O
or O
radiation O
therapy O
. O

There O
was O
no O
evidence O
of O
a O
statistically O
significant O
reduction O
in O
proportion O
of O
patients O
receiving O
RBC O
transfusions O
. O

The O
median O
survival O
was O
shorter O
in O
the O
darbepoetin O
alfa O
treatment O
group O
than O
in O
the O
placebo O
group O
( O
8 O
months O
vs O
. O
10.8 O
months O
; O
HR O
1.30 O
, O
95 O
% O
CI O
: O
1.07 O
, O
1.57 O
) O
. O

Decreased O
Progression O
- O
free O
Survival O
and O
Overall O
Survival O
Study O
1 O
was O
a O
randomized O
, O
open-label O
, O
multicenter O
study O
in O
2,098 O
anemic B-Not_AE_Candidate
women O
with O
metastatic B-Not_AE_Candidate
breast I-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
who O
received O
first O
line O
or O
second O
line O
chemotherapy O
. O

This O
was O
a O
non O
inferiority O
study O
designed O
to O
rule O
out O
a O
15 O
% O
risk O
increase O
in O
tumor B-NonOSE_AE
progression I-NonOSE_AE
or O
death B-NonOSE_AE
of O
epoetin O
alfa O
plus O
standard O
of O
care O
( O
SOC O
) O
as O
compared O
with O
SOC O
alone O
. O

The O
median O
progression O
free O
survival O
( O
PFS O
) O
per O
investigator O
assessment O
of O
disease O
progression O
was O
7.4 O
months O
in O
each O
arm O
( O
HR O
1.09 O
, O
95 O
% O
CI O
: O
0.99 O
, O
1.20 O
) O
, O
indicating O
the O
study O
objective O
was O
not O
met O
. O

At O
the O
time O
of O
clinical O
data O
cutoff O
, O
1337 O
deaths B-NonOSE_AE
were O
reported O
. O

Median O
overall O
survival O
in O
the O
epoetin O
alfa O
plus O
SOC O
group O
was O
17.2 O
months O
compared O
with O
17.4 O
months O
in O
the O
SOC O
alone O
group O
( O
HR O
1.06 O
, O
95 O
% O
CI O
: O
0.95 O
, O
1.18 O
) O
. O

There O
were O
more O
deaths B-NonOSE_AE
from O
disease O
progression O
in O
the O
epoetin O
alfa O
plus O
SOC O
arm O
( O
59 O
% O
vs O
. O
56 O
% O
) O
and O
more O
thrombotic B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
the O
epoetin O
alfa O
plus O
SOC O
arm O
( O
3 O
% O
vs O
. O
1 O
% O
) O
. O

Study O
4 O
was O
a O
randomized O
, O
open-label O
, O
controlled O
, O
factorial O
design O
study O
in O
which O
darbepoetin O
alfa O
was O
administered O
to O
prevent O
anemia B-Not_AE_Candidate
in O
733 O
women O
receiving O
neo-adjuvant O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treatment O
. O

A O
final O
analysis O
was O
performed O
after O
a O
median O
follow-up O
of O
approximately O
3 O
years O
. O

The O
3-year O
survival O
rate O
was O
lower O
( O
86 O
% O
vs O
. O
90 O
% O
; O
HR O
1.42 O
, O
95 O
% O
CI O
: O
0.93 O
, O
2.18 O
) O
and O
the O
3-year O
relapse-free O
survival O
rate O
was O
lower O
( O
72 O
% O
vs O
. O
78 O
% O
; O
HR O
1.33 O
, O
95 O
% O
CI O
: O
0.99 O
, O
1.79 O
) O
in O
the O
darbepoetin O
alfa-treated O
arm O
compared O
to O
the O
control O
arm O
. O

Study O
5 O
was O
a O
randomized O
, O
open-label O
, O
controlled O
study O
that O
enrolled O
114 O
of O
a O
planned O
460 O
patients O
with O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
chemotherapy O
and O
radiotherapy O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
to O
maintain O
hemoglobin O
between O
12 O
and O
14 O
g/dL O
or O
to O
RBC O
transfusion O
support O
as O
needed O
. O

The O
study O
was O
terminated O
prematurely O
due O
to O
an O
increase O
in O
thromboembolic B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
in O
epoetin O
alfa-treated O
patients O
compared O
to O
control O
( O
19 O
% O
vs O
. O
9 O
% O
) O
. O

Both O
local O
recurrence O
( O
21 O
% O
vs O
. O
20 O
% O
) O
and O
distant O
recurrence O
( O
12 O
% O
vs O
. O
7 O
% O
) O
were O
more O
frequent O
in O
epoetin O
alfa-treated O
patients O
compared O
to O
control O
. O

Progression-free O
survival O
at O
3 O
years O
was O
lower O
in O
the O
epoetin O
alfa-treated O
group O
compared O
to O
control O
( O
59 O
% O
vs O
. O
62 O
% O
; O
HR O
1.06 O
, O
95 O
% O
CI O
: O
0.58 O
, O
1.91 O
) O
. O

Overall O
survival O
at O
3 O
years O
was O
lower O
in O
the O
epoetin O
alfa-treated O
group O
compared O
to O
control O
( O
61 O
% O
vs O
. O
71 O
% O
; O
HR O
1.28 O
, O
95 O
% O
CI O
: O
0.68 O
, O
2.42 O
) O
. O

Study O
6 O
was O
a O
randomized O
, O
placebo-controlled O
study O
in O
351 O
patients O
with O
head B-Not_AE_Candidate
and I-Not_AE_Candidate
neck I-Not_AE_Candidate
cancer I-Not_AE_Candidate
where O
epoetin O
beta O
or O
placebo O
was O
administered O
to O
achieve O
target O
hemoglobins O
> O
= O
14 O
and O
> O
= O
15 O
g/dL O
for O
women O
and O
men O
, O
respectively O
. O

Locoregional O
progression-free O
survival O
was O
significantly O
shorter O
in O
patients O
receiving O
epoetin O
beta O
( O
HR O
1.62 O
, O
95 O
% O
CI O
: O
1.22 O
, O
2.14 O
; O
p O
= O
0.0008 O
) O
with O
medians O
of O
406 O
days O
and O
745 O
days O
in O
the O
epoetin O
beta O
and O
placebo O
arms O
respectively O
. O

Overall O
survival O
was O
significantly O
shorter O
in O
patients O
receiving O
epoetin O
beta O
( O
HR O
1.39 O
, O
95 O
% O
CI O
: O
1.05 O
, O
1.84 O
; O
p O
= O
0.02 O
) O
. O

Decreased O
Locoregional O
C O
ontrol O
Study O
7 O
was O
a O
randomized O
, O
open-label O
, O
controlled O
study O
conducted O
in O
522 O
patients O
with O
primary B-Not_AE_Candidate
squamous I-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
of O
the O
head O
and O
neck O
receiving O
radiation O
therapy O
alone O
( O
no O
chemotherapy O
) O
who O
were O
randomized O
to O
receive O
darbepoetin O
alfa O
to O
maintain O
hemoglobin O
levels O
of O
14 O
to15.5 O
g/dL O
or O
no O
darbepoetin O
alfa O
. O

An O
interim O
analysis O
performed O
on O
484 O
patients O
demonstrated O
that O
locoregional O
control O
at O
5 O
years O
was O
significantly O
shorter O
in O
patients O
receiving O
darbepoetin O
alfa O
( O
RR O
1.44 O
, O
95 O
% O
CI O
: O
1.06 O
, O
1.96 O
; O
p O
= O
0.02 O
) O
. O

Overall O
survival O
was O
shorter O
in O
patients O
receiving O
darbepoetin O
alfa O
( O
RR O
1.28 O
, O
95 O
% O
CI O
: O
0.98 O
, O
1.68 O
; O
p O
= O
0.08 O
) O
. O

5.3 O
Hypertension B-OSE_Labeled_AE
Aranesp O
is O
contraindicated O
in O
patients O
with O
uncontrolled B-Not_AE_Candidate
hypertension I-Not_AE_Candidate
. O

In O
Aranesp O
clinical O
studies O
, O
approximately O
40 O
% O
of O
patients O
with O
CKD B-Not_AE_Candidate
required O
initiation O
or O
intensification O
of O
antihypertensive O
therapy O
during O
the O
early O
phase O
of O
treatment O
. O

Hypertensive B-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
and O
seizures B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
CKD B-Not_AE_Candidate
receiving O
Aranesp O
. O

Appropriately O
control O
hypertension B-Not_AE_Candidate
prior O
to O
initiation O
of O
and O
during O
treatment O
with O
Aranesp O
. O

Reduce O
or O
withhold O
Aranesp O
if O
blood O
pressure O
becomes O
difficult O
to O
control O
. O

Advise O
patients O
of O
the O
importance O
of O
compliance O
with O
antihypertensive O
therapy O
and O
dietary O
restrictions O
[ O
see O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
. O

5.4 O
Seizures O
Aranesp O
increases O
the O
risk O
of O
seizures B-OSE_Labeled_AE
in O
patients O
with O
CKD B-Not_AE_Candidate
. O

During O
the O
first O
several O
months O
following O
initiation O
of O
Aranesp O
, O
monitor O
patients O
closely O
for O
premonitory B-NonOSE_AE
neurologic I-NonOSE_AE
symptoms I-NonOSE_AE
. O

Advise O
patients O
to O
contact O
their O
healthcare O
practitioner O
for O
new-onset O
seizures B-NonOSE_AE
, O
premonitory B-NonOSE_AE
symptoms I-NonOSE_AE
, O
or O
change O
in O
seizure B-NonOSE_AE
frequency O
. O

5.5 O
Lack O
or O
Loss O
of O
Hemoglobin O
Response O
to O
Aranesp O
For O
lack O
or O
loss O
of O
hemoglobin O
response O
to O
Aranesp O
, O
initiate O
a O
search O
for O
causative O
factors O
( O
e.g. O
, O
iron B-NonOSE_AE
deficiency I-NonOSE_AE
, O
infection B-NonOSE_AE
, O
inflammation B-NonOSE_AE
, O
bleeding B-NonOSE_AE
) O
. O

If O
typical O
causes O
of O
lack O
or O
loss O
of O
hemoglobin O
response O
are O
excluded O
, O
evaluate O
for O
PRCA B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

In O
the O
absence O
of O
PRCA B-NonOSE_AE
, O
follow O
dosing O
recommendations O
for O
management O
of O
patients O
with O
an O
insufficient O
hemoglobin O
response O
to O
Aranesp O
therapy O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.6 O
Pure B-OSE_Labeled_AE
Red I-OSE_Labeled_AE
Cell I-OSE_Labeled_AE
Aplasia I-OSE_Labeled_AE
Cases O
of O
PRCA B-OSE_Labeled_AE
and O
of O
severe O
anemia B-OSE_Labeled_AE
, O
with O
or O
without O
other O
cytopenias B-OSE_Labeled_AE
that O
arise O
following O
the O
development O
of O
neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
erythropoietin I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
treated O
with O
Aranesp O
. O

This O
has O
been O
reported O
predominantly O
in O
patients O
with O
CKD B-Not_AE_Candidate
receiving O
ESAs O
by O
subcutaneous O
administration O
. O

PRCA B-NonOSE_AE
has O
also O
been O
reported O
in O
patients O
receiving O
ESAs O
for O
anemia B-Not_AE_Candidate
related O
to O
hepatitis B-Not_AE_Candidate
C I-Not_AE_Candidate
treatment O
( O
an O
indication O
for O
which O
Aranesp O
is O
not O
approved O
) O
. O

If O
severe O
anemia B-NonOSE_AE
and O
low B-NonOSE_AE
reticulocyte I-NonOSE_AE
count I-NonOSE_AE
develop O
during O
treatment O
with O
Aranesp O
, O
withhold O
Aranesp O
and O
evaluate O
patients O
for O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
erythropoietin I-NonOSE_AE
. O

Contact O
Amgen O
( O
1-800-77-AMGEN O
) O
to O
perform O
assays O
for O
binding O
and O
neutralizing B-NonOSE_AE
antibodies I-NonOSE_AE
. O

Permanently O
discontinue O
Aranesp O
in O
patients O
who O
develop O
PRCA B-NonOSE_AE
following O
treatment O
with O
Aranesp O
or O
other O
erythropoietin O
protein O
drugs O
. O

Do O
not O
switch O
patients O
to O
other O
ESAs O
. O

5.7 O
Serious O
Allergic O
Reactions O
Serious O
allergic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
including O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
bronchospasm B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
and O
urticaria B-OSE_Labeled_AE
may O
occur O
with O
Aranesp O
. O

Immediately O
and O
permanently O
discontinue O
Aranesp O
and O
administer O
appropriate O
therapy O
if O
a O
serious O
allergic B-NonOSE_AE
or O
anaphylactic B-NonOSE_AE
reaction I-NonOSE_AE
occurs O
. O

5.8 O
Severe O
Cutaneous B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Blistering B-OSE_Labeled_AE
and O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
Erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
and O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SJS I-OSE_Labeled_AE
) O
/ O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
, O
have O
been O
reported O
in O
patients O
treated O
with O
ESAs O
( O
including O
Aranesp O
) O
in O
the O
post-marketing O
setting O
. O

Discontinue O
Aranesp O
therapy O
immediately O
if O
a O
severe O
cutaneous B-NonOSE_AE
reaction I-NonOSE_AE
, O
such O
as O
SJS B-NonOSE_AE
/ O
TEN B-NonOSE_AE
, O
is O
suspected O
. O

5.9 O
Dialysis O
Management O
Patients O
may O
require O
adjustments O
in O
their O
dialysis O
prescriptions O
after O
initiation O
of O
Aranesp O
. O

Patients O
receiving O
Aranesp O
may O
require O
increased O
anticoagulation O
with O
heparin O
to O
prevent O
clotting B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
extracorporeal I-OSE_Labeled_AE
circuit I-OSE_Labeled_AE
during O
hemodialysis O
. O

